Anti-CyclinA [E43.2]

Cat. #151089

Anti-CyclinA [E43.2]

Cat. #: 151089

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 1-2 weeks

Target: Cyclin A

Class: Monoclonal

Application: WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Julian Gannon

Institute: Cancer Research UK, London Research Institute: Clare Hall Laboratories

Tool Details
Target Details

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CyclinA [E43.2]
  • Alternate name: CCNA1; Cyclin A1; Testicular Tissue Protein Li 34; CT146
  • Research fields: Cancer;Cell biology;Genetics
  • Clone: E43.2
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: WB
  • Description: E43.2 is excellent for detecting cyclin A, giving a strong signal with no background.
  • Immunogen: Human Cyclin A
  • Isotype: IgG2a
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Cyclin A
  • Target background: Cyclins bind to and regulate the activity of the Cyclin Dependent Protein Kinases (CDKs). Cyclin A is involved in the regulation of the cell cycle and is essential for progression through S phase. Cyclin A protein is absent in cells prior to S-phase, during which its levels increase and peak. Cyclin A is a marker for actively proliferating cells and for cells in S phase.


  • Application: WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C


  • Ahmed-Choudhury et al. 2005. Cancer Res. 65(7):2690-7. PMID: 15805267.
  • Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter.